Metastatic Prostate Cancer

• ExplOratory, Phase 0 Study to assess biodisTribution and PosItron EMission Tomography (PET) Imaging kinetics of [64Cu]Cu-PSMA-R2 in metaStat … Not authorised
  2023-508473-86-00 3
• A trial to learn how safe AZD9750 is and how well it works in people with metastatic prostate cancer when given with or without other antica … Pending
  2024-516976-14-00 7
• (Title in lay language): A trial to learn how safe AZD0516 is and how well it works with and without other cancer treatments in adults with … Recruiting
  2024-520026-11-00 7 2026-03-19
• A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with either JNJ-63723283 (c … Recruiting
  2022-503132-14-00 3 2025-06-30
• ReaLuP : Study on Re-treatment with Radiopharmaceutical Drug [177Lu]Lu-PSMA in Patients With Metastatic Castration-Resistant Prostate Cancer Recruiting
  2024-512043-22-00 4 2025-04-11
• Surgical treatment with or without apalutamide in subjects with high risk prostate cancer who are candidates for radical prostatectomy and s … Recruiting
  2024-515049-41-00 4 2024-07-12
• Phase I study of 225Ac-PSMA I&T in prostate cancer Recruiting
  2024-513729-22-01 2 2022-02-01
• Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer (PETRANHA) Recruitment ended
  2023-508536-64-00 9 2022-05-17
• A Phase 3 Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment … Recruitment ended
  2023-503254-12-00 5 2019-03-06
• Randomised phase 3 trial of enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer: ENZAMET Recruitment ended
  2024-516137-13-00 5 2014-12-18
• A Phase 1b Open-Label, Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ARV-110 in Combination with Abiraterone … Ended
  2024-516661-37-00 3 2022-07-27

Showing 1–11 of 11 trials